Revolution Medicines
1 products tracked · names used in filings: Revolution Medicines
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Wed 26 Aug 2026🇺🇸 FDA approval
FDA approves Rasonque (daraxonrasib), a new medicine
Revolution Medicines; NDA220910; New molecular entity, Priority review; tablet · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Rasonque daraxonrasib | Approved | 2026-08-26 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.